CD33-Targeted Therapies: Beating the Disease or Beaten to Death?

Joseph E. Maakaron, John Rogosheske, Meixiao Long, Veronika Bachanova, Alice S. Mims

Research output: Contribution to journalReview articlepeer-review

Abstract

CD33 is a transmembrane protein that is found on cells of myeloid lineage. It is also intensely expressed on acute myeloid leukemia (AML) progenitor cells but not on normal stem cells. It internalizes on binding and dimerization, making it a specific and ideal target for AML therapeutics and drug delivery. Several targeted therapies have been tested and many are still currently in development. Gemtuzumab ozogamicin was the first and only CD33-directed antibody-drug conjugate to be US Food and Drug Administration approved for AML. Other targeted agents have not achieved such success. Promising new strategies include cellular therapy mechanisms and linker molecules. This is an exciting target that requires a considerable amount of precision to yield clinical benefit.

Original languageEnglish (US)
Pages (from-to)7-17
Number of pages11
JournalJournal of Clinical Pharmacology
Volume61
Issue number1
DOIs
StatePublished - Jan 2021

Bibliographical note

Funding Information:
This work was not supported by any external funding.

Keywords

  • 161533 TriKE
  • AMG 330
  • AMV564
  • AVE9633
  • CD33
  • IMGN779
  • SGN-CD33A
  • acute myeloid leukemia
  • chimeric antigen receptor T-cell therapies
  • gemtuzumab ozogamicin
  • lintuzumab
  • vadastuximab talirine

PubMed: MeSH publication types

  • Journal Article
  • Review

Fingerprint Dive into the research topics of 'CD33-Targeted Therapies: Beating the Disease or Beaten to Death?'. Together they form a unique fingerprint.

Cite this